<!doctype html>
<html>
<head>
<meta charset="UTF-8">
<meta name="apple-mobile-web-app-capable" content="yes">
<meta name="viewport" content="width=device-width initial-scale=1, user-scalable=no">
<meta name="apple-mobile-web-app-title" content="AstraZeneca | LYNPARZA">
<title>AstraZeneca | LYNPARZA</title>
<link rel="stylesheet" type="text/css" href="css/animate.min.css" />
<link rel="stylesheet" type="text/css" href="css/style.css" />
<script src="http://ajax.googleapis.com/ajax/libs/jquery/1.9.1/jquery.min.js"></script>
<style type="text/css">

.feature {width:825px; height:350px; margin-top: 100px;}
.footText {margin-top: 10px; font-family: "HelveticaNeueLTStd"; line-height: 16px; font-size: 12px; color: #506061;}

ul {list-style: none;}

table{
    width:850px;
    height:445px;
    border-bottom:2px solid #006185;
}

table > tbody > tr:first-child > td {color:white; font-size: 14px; line-height: 15x; font-family: "lexiRegular";
vertical-align: middle;text-align: center; height: 44px; }

table > tbody > tr > td {font-family: "HelveticaNeueLTStd"; text-align: center; font-size: 14px; color:#3f4444; vertical-align: middle; border-right:1px solid #003865; padding-right: 10px;
}



table > tbody > tr:first-child > td, table > tbody > tr > td:last-child { border: none; }


table > tbody > tr > td:first-child{padding-left: 10px; text-align: center; font-family: "helveticaBold";}
table > tbody > tr:first-child > td {font-family: "lexiRegular";}

table > tbody > tr:first-child > td:nth-child(4){text-align:center; }

table > tbody > tr:nth-child(1n + 1) {background-color: #bbced9;}
table > tbody > tr:nth-child(2n + 1){background-color: #e4ecf0;}

table > tbody > tr:first-child {background-color: #003665;}

table > tbody > tr:nth-child(n + 2) > td:nth-child(4) {
	text-align: left; line-height: 16px;
	font-family: "HelveticaNeueLTStd"; font-size: 14px; width:507px; height:94px;}

table > tbody > tr:nth-child(n + 2) > td:nth-child(4) > ul {padding-left:15px; list-style: disc;}

table > tbody > tr:nth-child(n + 2) > td:last-child > ul {width: 56px; height: 57px; padding-left: 10px;}
table > tbody > tr:nth-child(n + 2) > td:last-child > ul > li { display: inline-block; width: 25px; height:23px; background-repeat: no-repeat;}

table > tbody > tr:nth-child(2) > td:last-child > ul > li:first-child {background-image: url('./img/002.png'); }
table > tbody > tr:nth-child(2) > td:last-child > ul > li:nth-child(2) {background-image: url('./img/003.png');  }
table > tbody > tr:nth-child(2) > td:last-child > ul > li:nth-child(3) {background-image: url('./img/008.png'); }

table > tbody > tr:nth-child(3) > td:last-child > ul > li:first-child {background-image: url('./img/005.png'); }
table > tbody > tr:nth-child(3) > td:last-child > ul > li:nth-child(2) {background-image: url('./img/006.png');  }
table > tbody > tr:nth-child(3) > td:last-child > ul > li:nth-child(3) {background-image: url('./img/007.png'); }
table > tbody > tr:nth-child(3) > td:last-child > ul > li:last-child {background-image: url('./img/008.png'); }

table > tbody > tr:nth-child(4) > td:last-child > ul > li:first-child {background-image: url('./img/008.png'); }
table > tbody > tr:nth-child(5) > td:last-child > ul > li:first-child {background-image: url('./img/010.png'); }


</style> 

</head>
<body>
	<section id="container">
	<header>
		<p>Several economic analyses have show Symbicort<sup>&reg;</sup> to be cost-effective<br />
           or the dominant (more effective at lower cost) treatment for COPD<sup>1-4</sup>
        </p>
	</header>
        <ul class="controls">
            <li class="r">R</li>
        </ul>
    	<article class="content">

        <table>
            <tbody>
                <tr>
                    <td>Regimen</td>
                    <td>Comparator</td>
                    <td>Study</td>
                    <td>Symbicort benefits</td>
                    <td>Country</td>
                </tr>
                <tr>
                    <td>Symbicort<br />+ Spiriva<sup>&reg;</sup></td>
                    <td>Spiriva<sup>&reg;</sup></td>
                    <td>CLIMB<br />(Mittmann<br /><em>et al</em>.<sup>1</sup>)</td>
                    <td>
                        <ul>
                            <li>Symbicort added to Spiriva<sup>&reg;</sup> was the dominant strategy compared
                                with placebo added to Spiriva<sup>&reg;</sup> in Australia and Canada and appears
                                to be a cost-effective strategy in Sweden
                            </li>
                            <li>
                                NNT to avoid one severe exacerbation per year (including hospitalisations)
                                using Symbicort + Spiriva<sup>&reg;</sup> vs Spiriva<sup>&reg;</sup> + placebo = 1.39
                            </li>
                        </ul>
                    </td>
                    <td>
                    	<ul>
                    		<li></li>
                    		<li></li>
                    		<li></li>
                    		<li></li>
                    	</ul>
                    </td>
                </tr>
                <tr>
                    <td>Symbicort<br />+ Spiriva<sup>&reg;</sup></td>
                    <td>Spiriva<sup>&reg;</sup></td>
                    <td>CLIMB<br />(Nielsen<br /><em>et al</em>.<sup>2</sup>)</td>
                    <td>
                    	<ul>
                    		<li>From a societal perspective, Symbicort + Spiriva<sup>&reg;</sup>
                    		was dominant in Denmark, Norway and Sweden; the ICER was estimate at €174 per
                    		exacerbation avoided in Finland
                    		</li>
                    		<li>
                    			From a health care perspective, Symbicort + Spiriva<sup>&reg;</sup> was 
                    			dominant in Norway; the ICERs were estimated at DKK 1,580 (€212),
                    			€307, SEK 1,573 (€165) per exacerbation avoided in Denmark, Finland
                    			and Sweden, respectively (2010)
                    		</li>
                    	</ul>
                    </td>
                    <td>
                    	<ul>
                    		<li></li>
                    		<li></li>
                    		<li></li>
                    		<li></li>
                    	</ul>
                    </td> 
                </tr>
                <tr>
                    <td>Symbicort</td>
                    <td>Seretide<sup>&reg;</sup></td>
                    <td>PATHOS*<br />(Hedegaard<br /><em>et al.</em><sup>3</sup>)</td>
                    <td>
                    	<ul>
                    		<li>Annual exacerbation rates: 0.800 with Symbicort; 1.090 with Seretide
                    		<sup>&reg</sup> (26.6% reduction, P< 0.0001)</li>
                    		<li>Symbicort treatment was associated with being more cost-saving compared
                    		with Seretide<sup>&reg;</sup> treatment (total average annual per patient cost
                    		of SEK 12,580 [€1,318] and SEK 15,979 [€1,675], respectively)</li>
                    		<li>Symbicort was associated with being the dominant strategy (more effective
                    		at lower cost)</li>
                    		<li>[2010 Swedish unit costs; 2,734 patients in each treatment group]</li>
                    	</ul>
                    </td>
                    <td>
                    	<ul>
                    		<li></li>
                    		<li></li>
                    		<li></li>
                    		<li></li>
                    	</ul>
                    </td>
                </tr>
                <tr>
                    <td>Symbicort</td>
                    <td>Seretide<sup>&reg;</sup></td>
                    <td>PATHOS*<br />(Roggeri<br /><em>et al</em>.<sup>4</sup>)</td>
                    <td>
                    	<ul>
                    		<li>
                    			From a health care perspective, the treatment of a patient for one year with
                    			Symbicort was associated with a saying of €499.90 (€195.10 for drugs,
                    			€193.10 for COPD hospitalisations and €111.70 for pneumonia hospitalisations)
                    			corresponding to a 27.6% decrease vs Seretide<sup>&reg;</sup>
                    		</li>
                    	</ul>
                    </td>
                    <td>
                    	<ul>
                    		<li></li>
                    		<li></li>
                    		<li></li>
                    		<li></li>
                    	</ul>
                    </td> 
                </tr>

            </tbody>
        </table>
    		<p class="footnote">*Observational study using data from primary care medical records. Note: all studies are from a health care perspecitve
    		<br />References: 1.Mittmann Netal. Pharmacoeconomics 2011;29(5):403-14.2.Nielsen Retal. Respir Med 2013; 107(11):709-21.3.
    		Hedegaard Metal. PRS21.ISPOR 2012.<br />4. Roggeri A et al. Int J Chron Obstruct Pulmon Dis 2014;9:569-76.</p>

        </article>

    </section>

<script type="text/javascript" src="js/jquery-1.11.0.min.js"></script>
<script type="text/javascript" src="js/touchy.js"></script>
<script type="text/javascript" src="js/script.js"></script>
<script type="text/javascript">
	$( function(){

	});



</script>
</body>
</html>
